drugset / Trial / NCT01198028

Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma

NCT01198028 ↗

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well erlotinib works in treating participants with skin squamous cell carcinoma that has spread to other places in the body or has come back. Drugs used in chemotherapy, such as erlotinib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Timeline

Start
2011-03-10
Primary completion
2019-05-01
Completion
2019-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule 150 mg Oral